RKIP suppresses the proliferation and metastasis of breast cancer cell lines through up-regulation of miR-185 targeting HMGA2

Archives of Biochemistry and Biophysics

Volumn 610, Issue , 2016, Pages 25-32

  Zou, Qiongyan ^a   Wu, Haijun ^b   Fu, Fenfen ^c   Yi, Wenjun ^a   Pei, Lei ^a   Zhou, Meirong ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Breast cancer; Growth; HMGA2; Invasion; MIR 185; RKIP

Indexed keywords

HIGH MOBILITY GROUP A2 PROTEIN; MESSENGER RNA; MICRORNA; MICRORNA 185; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; MIRN185 MICRORNA, HUMAN; PEBP1 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ARTICLE; BINDING SITE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER GROWTH; CELL GROWTH; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR INVASION; UPREGULATION; BREAST TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; MCF-7 CELL LINE; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HMGA2 PROTEIN; HUMANS; MCF-7 CELLS; MICRORNAS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; RNA, MESSENGER; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84990062967     PISSN: 00039861     EISSN: 10960384     Source Type: Journal    
DOI: 10.1016/j.abb.2016.09.007     Document Type: Article

References (38)

1. [1] Redig, A.J., McAllister, S.S., Breast cancer as a systemic disease: a view of metastasis. J. Intern Med. 274 (2013), 113–126.
2. [2] Holmen, S.L., Williams, B.O., Essential role for Ras signaling in glioblastoma maintenance. Cancer Res. 65 (2005), 8250–8255.
3. [3] Jeuken, J., van den Broecke, C., Gijsen, S., Boots-Sprenger, S., Wesseling, P., RAS/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations. Acta Neuropathol. 114 (2007), 121–133.
4. [4] Goldberg, L., Kloog, Y.A., Ras inhibitor tilts the balance between Rac and Rho and blocks phosphatidylinositol 3-kinase-dependent glioblastoma cell migration. Cancer Res. 66 (2006), 11709–11717.
5. [5] Hjelmeland, A.B., Lattimore, K.P., Fee, B.E., Shi, Q., Wickman, S., Keir, S.T., Hjelmeland, M.D., et al. The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion. Mol. Cancer Ther. 6 (2007), 2449–2457.
6. [6] Zeng, L., Imamoto, A., Rosner, M.R., Raf kinase inhibitory protein (RKIP): a physiological regulator and future therapeutic target. Expert Opin. Ther. Targets 12 (2008), 1275–1287.
7. [7] Granovsky, A.E., Rosner, M.R., Raf kinase inhibitory protein: a signal transduction modulator and metastasis suppressor. Cell Res. 18 (2008), 452–457.
8. [8] Klysik, J., Theroux, S.J., Sedivy, J.M., Moffit, J.S., Boekelheide, K., Signaling crossroads: the function of Raf kinase inhibitory protein in cancer, the central nervous system and reproduction. Cell Signal 20 (2008), 1–9.
9. [9] Sun, M., Gomes, S., Chen, P., Frankenberger, C.A., Sankarasharma, D., Chung, C.H., Chada, K.K., et al. RKIP and HMGA2 regulate breast tumor survival and metastasis through lysyl oxidase and syndecan-2. Oncogene 33 (2014), 3528–3537.
10. [10] Yun, J., Frankenberger, C.A., Kuo, W.L., Boelens, M.C., Eves, E.M., Cheng, N., Liang, H., et al. Signalling pathway for RKIP and Let-7 regulates and predicts metastatic breast cancer. EMBO J. 30 (2011), 4500–4514.
11. [11] Hebert, C., Norris, K., Scheper, M.A., Nikitakis, N., Sauk, J.J., High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Mol. Cancer, 6, 2007, 5.
12. [12] Motoyama, K., Inoue, H., Nakamura, Y., Uetake, H., Sugihara, K., Mori, M., Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family. Clin. Cancer Res. 14 (2008), 2334–2340.
13. [13] Hristov, A.C., Cope, L., Reyes, M.D., Singh, M., Iacobuzio-Donahue, C., Maitra, A., Resar, L.M., HMGA2 protein expression correlates with lymph node metastasis and increased tumor grade in pancreatic ductal adenocarcinoma. Mod. Pathol. 22 (2009), 43–49.
14. [14] Meyer, B., Loeschke, S., Schultze, A., Weigel, T., Sandkamp, M., Goldmann, T., Vollmer, E., et al. HMGA2 overexpression in non-small cell lung cancer. Mol. Carcinog. 46 (2007), 503–511.
15. [15] Chiappetta, G., Ferraro, A., Vuttariello, E., Monaco, M., Galdiero, F., De Simone, V., Califano, D., et al. HMGA2 mRNA expression correlates with the malignant phenotype in human thyroid neoplasias. Eur. J. Cancer 44 (2008), 1015–1021.
16. [16] Miyazawa, J., Mitoro, A., Kawashiri, S., Chada, K.K., Imai, K., Expression of mesenchyme-specific gene HMGA2 in squamous cell carcinomas of the oral cavity. Cancer Res. 64 (2004), 2024–2029.
17. [17] Malek, A., Bakhidze, E., Noske, A., Sers, C., Aigner, A., Schafer, R., Tchernitsa, O., HMGA2 gene is a promising target for ovarian cancer silencing therapy. Int. J. Cancer 123 (2008), 348–356.
18. [18] Liu, H., Li, P., Li, B., Sun, P., Zhang, J., Wang, B., Jia, B., RKIP inhibits gastric cancer cell survival and invasion by regulating the expression of HMGA2 and OPN. Tumour Biol. 35 (2014), 11949–11958.
19. [19] Lei, X., Chang, L., Ye, W., Jiang, C., Zhang, Z., Raf kinase inhibitor protein (RKIP) inhibits the cell migration and invasion in human glioma cell lines in vitro. Int. J. Clin. Exp. Pathol. 8 (2015), 14214–14220.
20. [20] Chen, Z., Cheng, Q., Ma, Z., Xi, H., Peng, R., Jiang, B., Overexpression of RKIP inhibits cell invasion in glioma cell lines through upregulation of miR-98. Biomed. Res. Int., 2013, 2013, 695179.
21. [21] Farooqi, A.A., Li, Y., Sarkar, F.H., The biological complexity of RKIP signaling in human cancers. Exp. Mol. Med., 47, 2015, e185.
22. [22] Dangi-Garimella, S., Yun, J., Eves, E.M., Newman, M., Erkeland, S.J., Hammond, S.M., Minn, A.J., et al. Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7. EMBO J. 28 (2009), 347–358.
23. [23] Claes, A., Idema, A.J., Wesseling, P., Diffuse glioma growth: a guerilla war. Acta Neuropathol. 114 (2007), 443–458.
24. [24] Louis, D.N., Ohgaki, H., Wiestler, O.D., Cavenee, W.K., Burger, P.C., Jouvet, A., Scheithauer, B.W., et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114 (2007), 97–109.
25. [25] Wen, P.Y., Kesari, S., Malignant gliomas in adults. N. Engl. J. Med. 359 (2008), 492–507.
26. [26] Tang, J., Ahmad, A., Sarkar, F.H., The role of microRNAs in breast cancer migration, invasion and metastasis. Int. J. Mol. Sci. 13 (2012), 13414–13437.
27. [27] Kim, H.S., Kim, G.Y., Lim, S.J., Kim, Y.W., Loss of Raf-1 kinase inhibitory protein in pancreatic ductal adenocarcinoma. Pathology 42 (2010), 655–660.
28. [28] Xu, Y.F., Yi, Y., Qiu, S.J., Gao, Q., Li, Y.W., Dai, C.X., Cai, M.Y., et al. PEBP1 downregulation is associated to poor prognosis in HCC related to hepatitis B infection. J. Hepatol. 53 (2010), 872–879.
29. [29] Chatterjee, D., Sabo, E., Tavares, R., Resnick, M.B., Inverse association between Raf Kinase Inhibitory Protein and signal transducers and activators of transcription 3 expression in gastric adenocarcinoma patients: implications for clinical outcome. Clin. Cancer Res. 14 (2008), 2994–3001.
30. [30] Martinho, O., Gouveia, A., Silva, P., Pimenta, A., Reis, R.M., Lopes, J.M., Loss of RKIP expression is associated with poor survival in GISTs. Virchows Arch. 455 (2009), 277–284.
31. [31] Liu, H., Li, P., Li, B., Sun, P., Zhang, J., Wang, B., Jia, B., RKIP suppresses gastric cancer cell proliferation and invasion and enhances apoptosis regulated by microRNA-224. Tumour Biol. 35 (2014), 10095–10103.
32. [32] Alajez, N.M., Shi, W., Hui, A.B., Bruce, J., Lenarduzzi, M., Ito, E., Yue, S., et al. Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98. Cell Death Dis., 1, 2010, e85.
33. [33] Li, S., Ma, Y., Hou, X., Liu, Y., Li, K., Xu, S., Wang, J., MiR-185 acts as a tumor suppressor by targeting AKT1 in non-small cell lung cancer cells. Int. J. Clin. Exp. Pathol. 8 (2015), 11854–11862.
34. [34] Tang, H., Liu, P., Yang, L., Xie, X., Ye, F., Wu, M., Liu, X., et al. miR-185 suppresses tumor proliferation by directly targeting E2F6 and DNMT1 and indirectly upregulating BRCA1 in triple-negative breast cancer. Mol. Cancer Ther. 13 (2014), 3185–3197.
35. [35] Tan, Z., Jiang, H., Wu, Y., Xie, L., Dai, W., Tang, H., Tang, S., miR-185 is an independent prognosis factor and suppresses tumor metastasis in gastric cancer. Mol. Cell Biochem. 386 (2014), 223–231.
36. [36] Jing, R., Chen, W., Wang, H., Ju, S., Cong, H., Sun, B., Jin, Q., et al. Plasma miR-185 is decreased in patients with esophageal squamous cell carcinoma and might suppress tumor migration and invasion by targeting RAGE. Am. J. Physiol. Gastrointest. Liver Physiol. 309 (2015), G719–G729.
37. [37] Schuierer, M.M., Bataille, F., Hagan, S., Kolch, W., Bosserhoff, A.K., Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines. Cancer Res. 64 (2004), 5186–5192.
38. [38] Fu, Z., Smith, P.C., Zhang, L., Rubin, M.A., Dunn, R.L., Yao, Z., Keller, E.T., Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J. Natl. Cancer Inst. 95 (2003), 878–889.